Climb Bio, Inc. (CLYM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLYM SEC filings page.
This page shows Climb Bio, Inc. (CLYM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Climb Bio remains a cash-consuming development business, with no reported revenue and rising research spending funded largely without debt.
FY2025’s net loss narrowed to$59.9M , while operating cash outflow more than tripled from FY2024. The divergence coincided with R&D reaching$46.7M , indicating that improved accounting earnings did not translate into improved cash consumption.
The balance sheet is lightly debt-funded: total liabilities were
Nearly all FY2025 operating cash outflow became free-cash-flow outflow: FCF was
Financial Health Signals
Climb Bio, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Climb Bio, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Climb Bio, Inc. reported a net loss of $59.9M while operations used $54.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Climb Bio, Inc.'s EBITDA was -$15.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 44.1% from the same quarter a year earlier. Against the prior quarter it is down 1.0%.
Climb Bio, Inc. reported -$13.5M in net income in Q2 2026. This represents a decrease of 55.8% from the same quarter a year earlier. Against the prior quarter it is up 1.6%.
Climb Bio, Inc. earned -$0.18 per diluted share (EPS) in Q2 2026. This represents a decrease of 38.5% from the same quarter a year earlier. Against the prior quarter it is up 10.0%.
Not reported for Q2 2026.
Cash & Balance Sheet
Climb Bio, Inc. held $44.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Climb Bio, Inc.'s ROE was -5.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.6 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Climb Bio, Inc. invested $9.7M in research and development in Q2 2026. This represents an increase of 47.7% from the same quarter a year earlier. Against the prior quarter it is up 3.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
CLYM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $9.7M+47.7% | $9.4M-45.9% | N/A | $9.1M+45.4% | $6.6M+528.6% | $17.3M+1488.2% | N/A | $6.2M+117.0% |
| SG&A Expenses | $5.6M+37.6% | $5.8M+2.6% | N/A | $5.8M+6.0% | $4.1M+11.9% | $5.7M+197.3% | N/A | $5.5M+158.4% |
| Operating Income | -$15.4M-43.9% | -$15.2M+33.9% | N/A | -$14.9M-26.9% | -$10.7M+81.1% | -$23.0M-666.0% | N/A | -$11.7M-134.6% |
| EBITDA | -$15.3M-44.1% | -$15.2M+34.1% | N/A | -$14.9M-26.7% | -$10.6M | -$23.0M | N/A | -$11.7M |
| Income Tax | N/A | N/A | N/A | N/A | N/A | $0 | N/A | $0 |
| Net Income | -$13.5M-55.8% | -$13.7M+34.0% | N/A | -$12.9M-44.9% | -$8.7M+84.2% | -$20.8M-1124.6% | N/A | -$8.9M-124.2% |
| EPS (Basic) | -$0.18-38.5% | -$0.20+35.5% | -$0.25-725.0% | -$0.19-46.2% | -$0.13+92.8% | -$0.31-416.7% | $0.04+130.8% | -$0.13+13.3% |
| EPS (Diluted) | -$0.18-38.5% | -$0.20+35.5% | -$0.25-725.0% | -$0.19-46.2% | -$0.13 | -$0.31 | $0.04 | -$0.13 |
| Diluted Shares (Avg) | 76M+12.7% | 68M+1.1% | N/A | 68M+1.5% | 68M | 67M | N/A | 67M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
CLYM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $246.3M+28.0% | $152.4M-24.1% | $167.7M-22.8% | $182.3M-18.0% | $192.4M-14.9% | $200.7M+83.6% | $217.2M+96.6% | $222.2M+97.1% |
| Current Assets | $186.6M+113.6% | $113.4M+13.1% | $105.8M-31.7% | $91.0M-54.0% | $87.4M-61.3% | $100.3M-8.2% | $154.9M+40.5% | $197.6M+75.8% |
| Cash & Equivalents | $44.1M+94.5% | $8.4M-71.2% | $35.7M-59.1% | $25.8M-82.3% | $22.7M-89.8% | $29.0M-72.4% | $87.2M-6.3% | $146.2M+154.9% |
| Short-Term Investments | $139.0M+124.1% | $101.2M+46.6% | $65.4M+2.7% | $61.1M+29.5% | $62.0M | $69.0M | $63.7M+365.4% | $47.2M-5.8% |
| Long-Term Investments | $56.1M-45.4% | $36.7M-63.2% | $59.6M-3.3% | $88.9M+261.9% | $102.7M | $99.8M | $61.6M | $24.6M |
| Total Liabilities | $6.7M+1.9% | $4.3M-41.7% | $7.3M+37.0% | $5.3M+54.9% | $6.6M+77.0% | $7.4M+149.3% | $5.3M+84.9% | $3.4M+14.4% |
| Current Liabilities | $5.9M-4.4% | $4.1M-42.1% | $7.0M+41.6% | $4.9M+44.6% | $6.2M+65.9% | $7.0M+138.5% | $4.9M+74.1% | $3.4M+18.0% |
| Non-Current Liabilities | $813K+95.0% | $216K-32.3% | $285K-24.0% | $352K | $417K | $319K | $375K+913.5% | $0-100.0% |
| Total Equity | $239.5M+29.0% | $148.1M-23.4% | $160.5M-24.3% | $177.0M-19.1% | $185.8M-16.4% | $193.4M+81.8% | $211.9M+96.9% | $218.8M+99.4% |
| Retained Earnings | -$316.9M-22.2% | -$303.4M-21.1% | -$289.7M-26.0% | -$272.2M-22.9% | -$259.3M-22.0% | -$250.7M-59.0% | -$229.9M-47.4% | -$221.5M-45.4% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CLYM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.5M+5.4% | -$14.4M+6.8% | -$15.6M-183.2% | -$12.1M-60.7% | -$11.1M-1571.4% | -$15.4M-748.5% | -$5.5M-483.0% | -$7.6M-316.5% |
| Depreciation & Amortization | $33K-13.2% | $38K | $30K | $29K | $38K | $0 | $0 | $0 |
| Stock-Based Compensation | $1.5M+46.2% | $1.6M-20.6% | N/A | $4.0M+36.1% | $1.0M+97.9% | $2.0M+334.8% | N/A | $2.9M+345.4% |
| Capital Expenditures | N/A | N/A | $0 | $109K | N/A | N/A | $0 | $0 |
| Free Cash Flow | N/A | N/A | -$15.6M-183.2% | -$12.2M-62.1% | N/A | N/A | -$5.5M-483.0% | -$7.6M-316.5% |
| Investing Cash Flow | -$57.3M-1296.5% | -$13.0M+69.7% | $25.5M+147.8% | $15.3M+121.3% | $4.8M+149.6% | -$42.8M-410.9% | -$53.4M-245.3% | -$71.8M-356.1% |
| Financing Cash Flow | $103.7M | $5K | -$21K-151.2% | $0-100.0% | $0-100.0% | $0-100.0% | $41K-85.8% | $2.3M+330.1% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CLYM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -5.6%-1.0pp | -9.3%+1.5pp | N/A | -7.3%-3.2pp | -4.7%+20.0pp | -10.8%-9.2pp | N/A | -4.1%-0.4pp |
| Return on Assets | -5.5%-1.0pp | -9.0%+1.3pp | N/A | -7.1%-3.1pp | -4.5%+19.8pp | -10.3%-8.8pp | N/A | -4.0%-0.5pp |
| Current Ratio | 31.45+17.4x | 27.86+13.6x | 15.16-16.3x | 18.38-39.4x | 14.08-46.3x | 14.25-22.8x | 31.41-7.5x | 57.73+19.0x |
| Debt-to-Equity | 0.030.0x | 0.030.0x | 0.050.0x | 0.030.0x | 0.040.0x | 0.040.0x | 0.030.0x | 0.020.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Climb Bio, Inc. CLYM | FY2025 | N/A | -$59.9M | N/A | $564.0M | — |
| Greenwich LifeSciences, Inc. GLSI | FY2025 | N/A | -$19.4M | N/A | $213.6M | — |
| Ventyx Biosciences, Inc. VTYX | FY2024 | N/A | -$135.1M | N/A | $1.0B | — |
| Aardvark Therapeutics, Inc. AARD | FY2025 | $5.1M | -$57.6M | N/A | $82.7M | 55/100 |
| Cabaletta Bio, Inc. CABA | FY2025 | N/A | -$167.9M | N/A | $239.1M | — |
| Kyverna Therapeutics, Inc. KYTX | FY2025 | N/A | -$161.3M | N/A | $350.7M | — |
Where Climb Bio, Inc. Ranks
Frequently Asked Questions
Is Climb Bio, Inc. profitable?
No, Climb Bio, Inc. (CLYM) reported a net income of -$59.9M in fiscal year 2025.
What is Climb Bio, Inc.'s EBITDA?
Climb Bio, Inc. (CLYM) had EBITDA of -$67.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Climb Bio, Inc.'s return on equity (ROE)?
Climb Bio, Inc. (CLYM) has a return on equity of -37.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Climb Bio, Inc.'s free cash flow?
Climb Bio, Inc. (CLYM) recorded an outflow of $54.5M in free cash flow during fiscal year 2025. This represents a -250.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Climb Bio, Inc.'s operating cash flow?
Climb Bio, Inc. (CLYM) recorded an outflow of $54.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Climb Bio, Inc.'s total assets?
Climb Bio, Inc. (CLYM) had $167.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Climb Bio, Inc.'s capital expenditures?
Climb Bio, Inc. (CLYM) invested $186K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Climb Bio, Inc. spend on research and development?
Climb Bio, Inc. (CLYM) invested $46.7M in research and development during fiscal year 2025.
What is Climb Bio, Inc.'s current ratio?
Climb Bio, Inc. (CLYM) had a current ratio of 15.16 as of fiscal year 2025, which is generally considered healthy.
What is Climb Bio, Inc.'s debt-to-equity ratio?
Climb Bio, Inc. (CLYM) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Climb Bio, Inc.'s return on assets (ROA)?
Climb Bio, Inc. (CLYM) had a return on assets of -35.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Climb Bio, Inc.'s P/E ratio?
Climb Bio, Inc. (CLYM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $564.0M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Climb Bio, Inc.'s price-to-sales ratio?
Climb Bio, Inc. (CLYM) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $564.0M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Climb Bio, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Climb Bio, Inc. (CLYM) held $160.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $54.4M over that year. Dividing the one by the other, the reported balance equals about 35 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Climb Bio, Inc.'s Piotroski F-Score?
Climb Bio, Inc. (CLYM) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Climb Bio, Inc.'s earnings high quality?
Climb Bio, Inc. (CLYM) reported a net loss of $59.9M while operations used $54.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.